Retrospective study evaluating the safety and efficacy of Nivolumab in treatment of relapsed or refractory Hodgkin's Lymphoma after allogenic hematopoietic cell transplantation

Trial Profile

Retrospective study evaluating the safety and efficacy of Nivolumab in treatment of relapsed or refractory Hodgkin's Lymphoma after allogenic hematopoietic cell transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2016

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2016 New trial record
    • 08 Dec 2015 Preliminary results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top